Action CDTX CIDARA THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Cidara Therapeutics, Inc.

Actions

CDTX

US1717572069

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/06/2024 		Varia. 5j. Varia. 1 janv.
11,94 USD +6,70% Graphique intraday de Cidara Therapeutics, Inc. +2,75% -24,81%
15/05 Cidara Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
25/04 Les plus fortes hausses du prémarché MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
Cidara Therapeutics: Q1 Earnings Snapshot
Earnings Flash (CDTX) CIDARA THERAPEUTICS Posts Q1 Revenue $8.5M
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cidara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
CDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTX
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – CDTX
CIDARA THERAPEUTICS ANNOUNCES DIVESTITURE OF REZAFUNGIN TO MUNDIPHARMA TO FOCUS ON ADVANCING THE CLINICAL DEVELOPMENT OF CLOUDBREAK DFC PIPELINE
Top Premarket Gainers
North American Morning Briefing : More Tech -2-
North American Morning Briefing : More Tech Earnings in Focus With GDP Data Adding to the Uncertainty
Cidara Therapeutics Shares Surge 42% After Re-Acquiring Flu Asset
Cidara Therapeutics, Inc. Announces Board Changes
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
Cidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
Mundipharma International Limited acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc..
Cidara Therapeutics, Inc. announced that it has received $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors
Cidara Therapeutics Q4 Loss Narrows as Sales Rise; Shares Surge Premarket
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CDTX
  4. Actualités Cidara Therapeutics, Inc.
  5. Autres langues